DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans.
Humoral and cellular immune responses have been produced by intramuscular vaccination with DNA plasmids expressing HIV-1 genes, suggesting possible immunotherapeutic and prophylactic value for these constructs. Vaccination with these constructs has decreased HIV-1 viral load in HIV-1-infected chimpanzees. In addition, naive (i.e. non-HIV-1-infected) chimpanzees were protected against a heterologous challenge with HIV-1. Ongoing phase I clinical trials show that therapeutic vaccinations indeed boost anti-HIV-1 immune responses in humans. A therapeutic phase I trial on humans with these constructs induced a good safety profile and also demonstrated an immunological potentiation. These findings indicate that further studies with these constructs in humans are warranted.
Ugen
K E
KE
University of South Florida College of Medicine, Department of Medical Microbiology and Immunology, Tampa 33612, USA. kugen@com1.med.usf.edu
Nyland
S B
SB
Boyer
J D
JD
Vidal
C
C
Lera
L
L
Rasheid
S
S
Chattergoon
M
M
Bagarazzi
M L
ML
Ciccarelli
R
R
Higgins
T
T
Baine
Y
Y
Ginsberg
R
R
Macgregor
R R
RR
Weiner
D B
DB
D016915:AIDS Vaccines / Q000627:therapeutic use*; D000595:Amino Acid Sequence; D000917:Antibody Formation / Q000276:immunology; D004279:DNA, Viral / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D015483:HIV Antibodies / Q000096:biosynthesis / Q000097:blood; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015658:HIV Infections / Q000097:blood / Q000276:immunology / Q000628:therapy*; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D008969:Molecular Sequence Data; D010957:Plasmids / Q000008:administration & dosage; D019444:Vaccines, DNA / Q000627:therapeutic use*
D016915:AIDS Vaccines; D004279:DNA, Viral; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D019444:Vaccines, DNA